Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
Identifieur interne : 003184 ( Main/Merge ); précédent : 003183; suivant : 003185Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
Auteurs : Michael Iskedjian [Canada] ; Thomas R. EinarsonSource :
- PharmacoEconomics [ 1170-7690 ] ; 2003.
Descripteurs français
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adult, Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Benserazide (economics), Benserazide (therapeutic use), Canada, Caregivers (economics), Cost Savings, Dopamine Agonists (economics), Dopamine Agonists (therapeutic use), Drug Costs, Health Care Costs, Humans, Indoles (economics), Indoles (therapeutic use), Levodopa (economics), Levodopa (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (economics), Treatment Outcome.
- MESH :
- chemical , economics : Antiparkinson Agents, Benserazide, Dopamine Agonists, Indoles, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Benserazide, Dopamine Agonists, Indoles, Levodopa.
- geographic : Canada.
- drug therapy : Parkinson Disease.
- economics : Caregivers, Parkinson Disease.
- Adult, Cost Savings, Drug Costs, Health Care Costs, Humans, Middle Aged, Treatment Outcome.
Abstract
Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa.
PubMed: 12515573
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001474
- to stream PubMed, to step Curation: 001474
- to stream PubMed, to step Checkpoint: 001474
- to stream Ncbi, to step Merge: 000272
- to stream Ncbi, to step Curation: 000272
- to stream Ncbi, to step Checkpoint: 000272
Links to Exploration step
pubmed:12515573Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.</title><author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name><affiliation wicri:level="1"><nlm:affiliation>PharmIdeas Research & Consulting Inc., Oakville, Ontario, Canada. skedji@pharmideas.com</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>PharmIdeas Research & Consulting Inc., Oakville, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R" last="Einarson">Thomas R. Einarson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12515573</idno><idno type="pmid">12515573</idno><idno type="wicri:Area/PubMed/Corpus">001474</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001474</idno><idno type="wicri:Area/PubMed/Curation">001474</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001474</idno><idno type="wicri:Area/PubMed/Checkpoint">001474</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001474</idno><idno type="wicri:Area/Ncbi/Merge">000272</idno><idno type="wicri:Area/Ncbi/Curation">000272</idno><idno type="wicri:Area/Ncbi/Checkpoint">000272</idno><idno type="wicri:doubleKey">1170-7690:2003:Iskedjian M:cost:analysis:of</idno><idno type="wicri:Area/Main/Merge">003184</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.</title><author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name><affiliation wicri:level="1"><nlm:affiliation>PharmIdeas Research & Consulting Inc., Oakville, Ontario, Canada. skedji@pharmideas.com</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>PharmIdeas Research & Consulting Inc., Oakville, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R" last="Einarson">Thomas R. Einarson</name></author></analytic><series><title level="j">PharmacoEconomics</title><idno type="ISSN">1170-7690</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiparkinson Agents (economics)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benserazide (economics)</term><term>Benserazide (therapeutic use)</term><term>Canada</term><term>Caregivers (economics)</term><term>Cost Savings</term><term>Dopamine Agonists (economics)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Costs</term><term>Health Care Costs</term><term>Humans</term><term>Indoles (economics)</term><term>Indoles (therapeutic use)</term><term>Levodopa (economics)</term><term>Levodopa (therapeutic use)</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (economics)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Dopamine Agonists</term><term>Indoles</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benserazide</term><term>Dopamine Agonists</term><term>Indoles</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Caregivers</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cost Savings</term><term>Drug Costs</term><term>Health Care Costs</term><term>Humans</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003184 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003184 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:12515573
|texte= Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:12515573" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |